Explore

Trendline Trendline
Linden Lake Labs Announces Acquisition of CrossBridge Bio by Eli Lilly

Linden Lake Labs Announces Acquisition of CrossBridge Bio by Eli Lilly

Linden Lake Labs Announces Acquisition of CrossBridge Bio by Eli Lilly
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs
Trendline Trendline
CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology
Trendline Trendline
Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
Daiichi Sankyo Sells Consumer Healthcare Unit to Suntory for $1.55 Billion

Daiichi Sankyo Sells Consumer Healthcare Unit to Suntory for $1.55 Billion

Daiichi Sankyo Sells Consumer Healthcare Unit to Suntory for $1.55 Billion
Trendline Trendline
GSK Advances Ovarian Cancer Treatment with Promising Clinical Results

GSK Advances Ovarian Cancer Treatment with Promising Clinical Results

GSK Advances Ovarian Cancer Treatment with Promising Clinical Results